Stock CERO CERO THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

CERo Therapeutics Holdings, Inc. Stock

Equities

CERO

US71902K1051

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
0.6732 USD -10.94% Intraday chart for CERo Therapeutics Holdings, Inc. -27.61% -93.88%
Jun. 06 CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 CI
May. 17 CERo Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Financials (USD)

Sales 2022 - Sales 2023 - Capitalization 68.71M
Net income 2022 - Net income 2023 -2M EV / Sales 2022 -
Net Debt 2022 174K Net Debt 2023 1.46M EV / Sales 2023 -
P/E ratio 2022
-346 x
P/E ratio 2023
-28.3 x
Employees 9
Yield 2022 *
-
Yield 2023
-
Free-Float 43.32%
More Fundamentals * Assessed data

Chart CERo Therapeutics Holdings, Inc.

Dynamic Chart

Latest news about CERo Therapeutics Holdings, Inc.

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 CI
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Premarket Decliners MT
Top Premarket Gainers MT
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients CI
CERo Therapeutics Holdings, Inc. announced that it expects to receive $25 million in funding from Arena Business Solutions Global SPC II, Ltd. CI
Top Premarket Decliners MT
Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics MT
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer CI
Phoenix Biotech Acquisition Corp. Announces Executive and Board Changes CI
Phoenix Biotech Acquisition Corp. Appoints Charles Carter as Chief Financial Officer CI
Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index CI
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc. CI
CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding CI
More news

Press releases CERo Therapeutics Holdings, Inc.

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 GL
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders GL
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes AQ
PHOX BIOT26 : CERo Therapeutics Investor Presentation PU
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients BU
More press releases

Quotes and Performance

1 day-10.94%
1 week-27.61%
Current month-27.61%
1 month-41.46%
3 months-82.96%
6 months-93.82%
Current year-93.88%
More quotes

Highs and lows

1 week
0.66
Extreme 0.66
1.02
1 month
0.66
Extreme 0.66
1.20
Current year
0.66
Extreme 0.66
12.80
1 year
0.66
Extreme 0.66
12.80
3 years
0.66
Extreme 0.66
12.80
5 years
0.66
Extreme 0.66
12.80
10 years
0.66
Extreme 0.66
12.80
More quotes

ETFs positioned on CERo Therapeutics Holdings, Inc.

Name Weight AuM 1st Jan change Investor Rating
ROBINSON ALTERNATIVE YIELD PRE-MERGER SPAC ETF - USD ETF Robinson Alternative Yield Pre-Merger SPAC ETF - USD
0.29% 12 M€ +0.52% -
More ETFs positioned on CERo Therapeutics Holdings, Inc.

Quotes

Date Price Change Volume
24-06-07 0.6732 -10.94% 364,038
24-06-06 0.7559 -16.47% 2,793,313
24-06-05 0.9049 -0.01% 28,804
24-06-04 0.905 -2.16% 18,790
24-06-03 0.925 -0.54% 72,115

Delayed Quote Nasdaq, June 07, 2024 at 04:30 pm EDT

More quotes

Company Profile

CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CERO THERAPEUTICS HOLDINGS, INC. Stock CERo Therapeutics Holdings, Inc.
-93.88% 10.14M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.72% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.19% 108B
BIONTECH SE Stock BioNTech SE
-4.93% 24.21B
ARGENX SE Stock argenx SE
+2.45% 22.78B
GENMAB A/S Stock Genmab A/S
-10.44% 17.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.31% 16.37B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.44% 13.58B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.89% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CERO Stock